MLTX — MoonLake Immunotherapeutics
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1821586 ·
Last close
$11.25
Market Cap
$957.45M
52W High
$23.29
52W Low
$9.46
ADV30
1,677,643
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -79,852,000 | -79,545,000 | 540,715,000 | 379,704,000 | 159,087,000 |
| Jun 2026 | 0 | — | -61,660,000 | -61,805,000 | 573,947,000 | 477,905,000 | 145,752,000 |
| Mar 2026 | 0 | — | -70,024,000 | -69,707,000 | 400,374,000 | 298,490,000 | 146,350,000 |
| Dec 2025 | 0 | — | -65,218,000 | -62,427,000 | 424,433,000 | 334,517,000 | 119,952,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-244,041,000
Investing CF
$-88,255,000
Financing CF
$364,633,000
CapEx
$-35,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.85
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-673,968,000
Inventory
—
Receivables
$8,948,000
ST Investments
$118,758,000
EBIT TTM
$-262,934,000
Pretax Income TTM
$-272,484,000
Interest Exp TTM
$9,550,000
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -244,834,000 | -227,318,000 | 424,433,000 | 119,952,000 | 304,481,000 | -196,007,000 |
| Dec 2024 | 0 | -143,091,000 | -118,936,000 | 477,933,000 | 24,542,000 | 446,825,000 | -116,587,000 |
| Dec 2023 | 0 | -54,123,000 | -36,007,000 | 526,540,115 | 13,049,096 | 495,675,683 | -42,778,000 |
| Dec 2022 | 0 | -65,061,417 | -49,973,249 | 76,843,301 | 8,076,603 | 48,898,296 | -55,893,900 |
TTM Snapshot
Revenues TTM
$-536,670,000
NetIncome TTM
$-263,666,000
OpCashFlow TTM
—
Assets (Latest)
$573,947,000
Forward EPS
$-3.33
Max Pain — expiry 2027-01-15
max pain strike: $11.00 · spot: $10.79 · call oi: 7,329 · put oi: 1,803
Expected Move to 2027-01-15:
±$3.50
(32.44%) —
implied range
$7.29 –
$14.29
· ATM straddle on $11.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPTX | Seaport Therapeutics, Inc. | $972.65M | $18.17 | — |
| JBIO | Jade Biosciences, Inc. | $979.40M | $15.40 | — |
| VSTM | Verastem, Inc. | $933.77M | $7.41 | — |
| SVRA | Savara Inc | $988.39M | $4.48 | — |
| ANRO | Alto Neuroscience, Inc. | $999.16M | $24.91 | — |
News headlines (Yahoo Finance, 1h cache)
MoonLake Immunotherapeutics (MLTX) Stock Could Be Above Fair Value On Book Value Concerns
2026-11-12 08:09 · Yahoo
MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
2026-11-11 22:50 · Yahoo
Is MoonLake Immunotherapeutics (MLTX) Cheap On Earnings Losses And Sonelokimab Milestones?
2026-11-11 03:13 · Yahoo
MoonLake Immunotherapeutics Stock In Focus After Quarterly Loss Update
2026-11-10 01:21 · Yahoo
MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View Holds
2026-10-25 10:15 · Yahoo
MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet Questions
2026-10-25 02:07 · Yahoo
MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”
2026-10-22 17:17 · Yahoo
MoonLake Immunotherapeutics Makes Case for Sonelokimab Approval, RBC Says
2026-10-16 15:35 · Yahoo
MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
2026-10-05 15:26 · Yahoo
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
2026-09-11 17:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.